FIELD: pharmaceutics.
SUBSTANCE: invention relates to levocarrimycin and use thereof for development of medicines for infectious diseases. Disclosed levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main component and comprises one of following components: isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, wherein content of isovalerylspiramycin III is not less than 30 wt%, total content of isovalerylspiramycin III, II and I is not less than 60 wt%, and content of acylspiramycin from 80 to 98 wt% and said levocarrimycin also contains spiramycin III and other components, among which content spiramycin III does not exceed 1.0%, and total content of other components ranges from 2.0 to 19 wt%, the spiramycin III is characterised by peaks at 2θ = 8.0°, 10.0°, 11.2°, 11.7°, 16.4°, 19.1°, 19.6°, 20.0°, 21.4°, 22.9°, 23.6° and 29.4°, spiramycin II is characterised by peaks at 2θ = 10.0°, 11.6°, 16.4°, 17.3°, 19.1°, 21.2°, 22.1°, 22.7°, 26.4°, 26.9°, 27.5° and 31.5° and spiramycin I is characterised by peaks at 2θ = 7.6°, 8.0°, 10.0°, 11.4°, 16.4°, 17.0°, 17.5°, 17.9°, 19.5°, 22.7°, 23.7° and 24.4° in X-ray powder diffraction, measured using radiation of Cu-Kα; said levocarrimycin is obtained by culturing cloned strain WSJ-195 bacteria which produce spiramycin, fermentation, extraction with subsequent chromatography and collecting desired peak; Ior, II levoisovalerylspiramycin recrystallisation III; mixing obtained crystalline levoisovalerylspiramycin I, II or III with levocarrimycin obtained by chromatography.
EFFECT: novel antibiotic formulation possessing higher solubility and efficiency.
18 cl, 46 ex, 6 tbl, 8 dwg
